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New technology in the Freedom® speech processor for cochlear implants was developed to 
improve how incoming acoustic sound is processed; this applies not only for new users, but also 
for previous generations of cochlear implants.
Aim: To identify the contribution of this technology - the Nucleus 22® - on speech perception tests 
in silence and in noise, and on audiometric thresholds.
Methods: A cross-sectional cohort study was undertaken. Seventeen patients were selected. The 
last map based on the Spectra® was revised and optimized before starting the tests. Troubleshooting 
was used to identify malfunction. To identify the contribution of the Freedom® technology for the 
Nucleus22®, auditory thresholds and speech perception tests were performed in free field in sound-
proof booths. Recorded monosyllables and sentences in silence and in noise (SNR = 0dB) were 
presented at 60 dBSPL. The nonparametric Wilcoxon test for paired data was used to compare groups.
Results: Freedom® applied for the Nucleus22® showed a statistically significant difference in all 
speech perception tests and audiometric thresholds.
Conclusion: The reedom® technology improved the performance of speech perception and 
audiometric thresholds of patients with Nucleus 22®.
ORIGINAL ARTICLE
Braz J Otorhinolaryngol.
2012;78(2):11-5. BJORL
Keywords:
adult,
audiometry,
cochlear implants,
speech discrimination 
tests,
speech perception.
.org
78(2)-ing.indb   11 27/03/2012   09:35:26
12
Brazilian Journal of otorhinolaryngology 78 (2) March/april 2012
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
INTRODUCTION
The first Brazilian multichannel cochlear implant 
surgeries were done in 19991, using the Spectra Bodyworn 
speech processor, from Cochlear Corporation®, which 
works well with the Nucleus 22® internal unit.
Throughout the years, new Technologies have been 
launched and cochlear implant companies developed 
speech processors for the previous internal units, avoiding 
the need for a new surgical procedure2-4.
In 2006, the Freedom® processor was launched, with 
new Technologies, among which two microphones and a 
new chip for signal processing, providing improvements 
in the processing of the input acoustic sound, not only for 
new users but also for patients with previous generations 
of cochlear implant.
In 2009, the replacement parts for the Nucleus 22® 
system were no longer manufactured. The Ministry of He-
alth, then, authorized the exchange, through the Brazilian 
Public Health Care System (SUS), of all the Nucleus 22® 
speech processors for the Freedom® speech processors.
In the scientific literature, numerous studies have 
shown the advantage in exchanging it for more modern 
processors; nonetheless, the direct exchange of the Spec-
tra® for the Freedom® was not studied, nor reported3,5.
Therefore, this study aimed at identifying the con-
tribution of the Freedom® speech processor technology 
for the first generation of the Nucleus 22® multichan-
nel cochlear implant. For that, we assessed the speech 
perception performance in silence and in noise and the 
audiometric thresholds with the Spectra® and Freedom® 
speech processors.
METHODS
This Project was presented to and approved by the 
Ethics Committee for the Analysis of Research projects of 
the institution under protocol number 0083/11. The pa-
tients were informed about the research and signed the 
informed consent form.
The study was a cross-sectional historical cohort, as-
sessing the results obtained with the update of the speech 
processor technology of the Nucleus 22® cochlear implant. 
We selected 43 patients implanted with the Nucleus 
22® in the Cochlear Implant Group of the University Hos-
pital of the Medical School of the University of São Paulo 
(USP). This way, five patients were no longer users of the 
cochlear implant, eight patients were already users of the 
Freedom® processor. The remaining 30 patients kept using 
the Spectra® processor and came to change the speech 
processor, offered by the Brazilian Government through 
the Ministry of Health.
In the study, we included the patients who were 
effectively using the implant (8 hours per day), and we 
took off the study those patients using it occasionally or 
those who did not have speech perception in the closed 
context. Six patients were not effective users, four patients 
were children and three patients did not have speech 
perception. Ultimately, the study included 17 patients.
The patients called followed the following protocol, 
broken down into three stages:
a. First stage: optimization of the current map and 
checking how the Spectra® processor worked
At this first stage, the last map being used by the 
patient with the Spectra® processor was reviewed and 
updated according to the programming routine with the 
Custom Sound 2.0® software. We studied the minimum 
stimulation levels (level T), in which the patient identi-
fies 100% of the presentations; the maximum levels of 
stimulation (level C) for those whom the electric current 
presented is comfortable and the level C intensity was 
balanced. Before doing the tests, the Spectra® processor 
functioning was checked, inspecting the wires, antenna 
transmission and microphone, using a signal checking 
device and the monitoring phone. Should any fault be 
found, the component would be replaced before the tests.
b. Second stage: programming the Freedom processor
We exchanged the Freedom® processor, maintaining 
the other parameters of the original map: total stimulation 
velocity and stimulation mode, without a signal pre-pro-
cessing strategy. We balanced the intensity of the T and 
C stimulation levels with the Custom Sound 2.0® software.
c. Third stage: assessing the audiometric thresholds and 
the speech perception tests
We carried out free field audiometry, with the Spec-
tra® and the Freedom® speech processors. In order to do 
the statistical calculation, we considered the mean values 
of the audiometric thresholds at 500 Hz; 1,000 Hz; 2,000 Hz 
and 4,000 Hz6 and the frequency thresholds individually.
In the same session, after programming all the 
maps, the following free field speech perception tests were 
carried out in a sound-treated booth, with the material 
recorded in a CD, presented at 60dBSPL7:
•	 Monossylables8,9;
•	 Open phrases in the silence10;
•	 Open phrases in noise with SNR = 0dB*10
* These tests were only employed when the phrase 
recognition performance in silence was higher than 50%.
The order in which the tests with the Spectra® 
processor maps and the new maps with the Freedom® 
processor was randomized using the software available 
at www.randomizer.org
The audiometric thresholds, percentage of correct 
answers in the speech perception tests are presented as 
means and standard deviation (SD) and also as median 
and the percentiles 25% and 75% (P25% and P75%, re-
spectively). Considering the small sample size, the ordinal 
nature and asymmetrical distributions of some variables, 
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the Wilcoxon non-parametric test for paired data was uti-
lized in order to compare the groups. The analysis of the 
parametric sensitivity utilizing the t test was carried out in 
all the comparisons and it did not change the results. A 
p < 0.05 was considered as statistically significant.
The statistical analyses were carried out using the 
STATA software (version 11.1).
RESULTS
Table 1 depicts the demographic data of the sample.
Most of the sample is made up of patients with 
more than eight years of experience using the cochlear 
implant. Only two were teenagers, and one of them had 
congenital deafness.
When we analyzed the contribution of the Freedom® 
for patients using the Nucleus 22®, we noticed a statistically 
significant difference in all the speech perception tests and 
in all audiometric thresholds, both individually as in the 
mean, except in 8,000 Hz (Tables 2 and 3).
DISCUSSION
Exchanging the Spectra® processor for the Freedom® 
proved that the technology improved the speech percep-
tion of Nucleus 22® users. Even when maintaining the same 
parameters of the stimulation mode, the total velocity and 
number of active electrodes, we can see a statistical differ-
ence in all the tests and in all the audiometric thresholds 
(Tables 2 and 3).
The scientific literature has shown that there are 
advantages when the speech processor is exchanged for 
more modern devices. Dodd et al.3 published their results 
concerning the exchange of the Spectra® box processor for 
the ESPrit® behind-the-year processor in 100 children; and 
they concluded that the conversion was feasible in all the 
cases studied, although the speech tests and audiometric 
thresholds did not show significant differences.
Santarelli et al.5 assessed the speech perception 
in 17 prelingual children users of the Nucleus 24® with 
the SPrint® and ESPrit 3G® processors, after one month 
Table 1. Sample demographic data.
Patients Gendera Age (years) Etiology
Deafness duration 
(years)
Duration of CIb 
Use
Number of active electrodes in the map 
(years) (active channels)
S1 M 50 Progressive 15 8 15 (17)
S2 M 68 Progressive 10 9 16 (18)
S3 F 47 Chicken pox 23 9 16(18)
S4 F 63 Otosclerosis 5 10 14 (16)
S5 M 82 Unknown 2 11 20 (20)
S6 M 49 Head Injury 2 10 20 (20)
S7 M 69 Progressive 3 9 18 (20)
S8 F 43 Meningitis 1 11 16 (18)
S9 F 15 Congenital 7 8 18 (20)
S10 M 29 Progressive 4 10 20 (20)
S11 F 47 Meningitis 28 10 20 (20)
S12 F 43 Meningitis 27 8 18 (20)
S13 M 58 Head Injury 2 8 18 (20)
S14 M 17 Meningitis 1 8 5 (5)
S15 F 30 Unknown 4 9 18 (20)
S16 M 50 Unknown 11 11 20 (20)
S17 F 44 Unknown 9 8 19 (19)
aM - male; F - female; bCI – cochlear implant.
Table 2. Speech perception results with both speech processors.
Spectra® Freedom®
Median (P25%, P75%c) Mean (SDd) ne Median (P25%, P75%c) Mean (SDd) ne pf(Wilcoxon)
Monosyllables 16 (4, 32) 20.9 (18.2) 17 36 (20, 56) 34.8 (19.9) 17 0.0011*
Phrases in noise 0 (0, 60) 26.5 (32.8) 17 40 (10, 80) 46.5 (36.7) 17 0.0021*
Phrases in silence 20 (0, 30) 20.0 (18.7) 9 60 (60, 70) 56.7 (26.0) 9 0.0174*
cP25% - 25% percentage; P75% - 75% percentage ; dSD – standard deviation; en – number of patients; fp < 0.05 (*) – statistically significant result.
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Table 3. Results from the audiometric thresholds with both speech processors.
Spectra® Freedom®
Median (P25%, P75%c) Mean (DPd) ne Median (P25%, P75%c) Mean (DPd) ne pf(Wilcoxon)
250 Hz 50 (45, 55) 49.4 (13.3) 17 35 (30, 40) 35.0 (9.8) 17 0.0004*
500 Hz 55 (45, 55) 52.1 (7.5) 17 40 (35, 40) 37.6 (5.6) 17 0.0004*
1000 Hz 45 (45, 50) 47.4 (6.6) 17 30 (25, 35) 29.7 (6.2) 17 0.0002*
1500 Hz 45 (40, 50) 46.5 (8.4) 17 30 (25, 35) 30.0 (8.8) 17 0.0003*
2000 Hz 50 (40, 55) 47.6 (8.9) 17 30 (25, 35) 31.2 (8.2) 17 0.0003*
3000 Hz 50 (45, 55) 49.1 (8.9) 17 35 (25, 40) 33.5 (9.3) 17 0.0005*
4000 Hz 55 (45, 55) 53.5 (9.5) 17 45 (30, 45) 38.5 (9.1) 17 0.0004*
6000 Hz 55 (45, 65) 58.2 (12.9) 17 40 (30, 50) 41.2 (16.3) 17 0.0007*
8000 Hz 60 (50, 75) 63.5 (15.2) 17 80 (70, 90) 74.7 (16.4) 17 0.0084*
BIAPg 48.7 (45, 53.7) 50.1 (6.3) 17 35 (28.7, 38.7) 34.3 (5.9) 17 0.0003*
c P25% - 25% percentage; P75% - 75% percentage; d SD – standard deviation; e n – number of patients; f p < 0.05 (*) – statistically significant 
result; g BIAP, 1996 – mean value of the 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz thresholds.
using the Freedom® processor. As results, the children 
had a significant improvement in the dissyllable words in 
the presence of noise, identification of consonants and 
phrase recognition. These improvements in phonemic dis-
crimination may be explained by an increase in the input 
dynamic field with the new processor. They concluded 
that the speech perception was higher with the Freedom®, 
being advisable to exchange for the new generation of 
processors. Moreover, all the children preferred the new 
processor.
This shows the importance and the care taken by 
cochlear implant manufacturers in developing new proces-
sors, matching the internal units of previous generations, 
so that these patients may enjoy the new technology and, 
consequently, improve their performance, but also enable 
more flexibility in programming, keeping the characteristics 
and the preference of the old program used by the patient.
The possibility of keeping the same parameters of 
the old processor in use shows that only changes to the 
microphone and the signal processing have been enough 
to the processor’s contribution in improving speech per-
ception.
One of the parameters maintained was the stimula-
tion mode. When one electrode is stimulated, the current 
flows from the active electrode to the ground one; and 
the broader the spacing between the electrodes the lower 
the necessary current.
Although the Freedom® has the BP+3 (bipolar, one 
active electrode and another as indifferent) stimulation 
mode as a standard for users of the Nucleus 22®, all the 
patients could maintain their modes of stimulation. With 
the aim of analyzing only the benefit of all the param-
eters studied, without harming the use of batteries, the 
stimulation modes utilized were maintained, i.e. BP+1 for 
all, except one patient who used the CG mode (common 
ground uses all the electrodes as different electrodes). 
Battery use was measured by the Custom Sound 2.0® 
software, finding an average of 8.6 hours for rechargeable 
batteries and 24.1 hours for the three 675 batteries. There 
were only two patients who had problems with battery 
consumption, with only 6 hours of battery life, which was 
solved by changing the power of the antenna magnet.
In this same sample, other technological resources 
were analyzed, as the effect of the frequency allocation 
table and the T-SPL effect of 25dB and that of the C-SPL 
of 65dB, which will be published later.
CONCLUSION
The Freedom® processor technology for users of the 
Nucleus 22® showed a statistically significant improvement 
in all speech tests in silent environments at 60 dB and in 
noise, with a signal/noise ratio of 0 dB, as well as in all 
audiometric thresholds.
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